Co-Diagnostics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Dwight Egan

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	29.7%
Dienstverband CEO	11.6yrs
Eigendom CEO	1.2%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Dwight Egan's beloning veranderd ten opzichte van Co-Diagnostics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$39m
Dec 31 2023	US$1m	US$375k	-US$35m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$32m
Dec 31 2022	US$2m	US$366k	-US$14m
Sep 30 2022	n/a	n/a	US$15m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	US$40m
Dec 31 2021	US$2m	US$350k	US$37m
Sep 30 2021	n/a	n/a	US$42m
Jun 30 2021	n/a	n/a	US$46m
Mar 31 2021	n/a	n/a	US$51m
Dec 31 2020	US$1m	US$309k	US$42m
Sep 30 2020	n/a	n/a	US$28m
Jun 30 2020	n/a	n/a	US$10m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$460k	US$275k	-US$6m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$474k	US$275k	-US$6m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$210k	US$195k	-US$7m

Compensatie versus markt: De totale vergoeding ($USD 1.26M ) Dwight } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 492.53K ).

Compensatie versus inkomsten: De vergoeding van Dwight is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Dwight Egan (71 yo)

11.6yrs

Tenure

US$1,261,300

Compensatie

Mr. Dwight H. Egan serves as the Chairman & Chief Executive Officer and was President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan has been engaged in private investment bus...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Dwight Egan	Chairman & CEO	no data	US$1.26m	1.15% € 408.8k
Brian Brown	CFO & Company Secretary	3.8yrs	US$1.04m	0.91% € 323.6k
Richard Abbott	President	less than a year	geen gegevens	1.85% € 657.8k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	11.6yrs	US$237.50k	geen gegevens
David Nielsen	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Dan Bohrer	Vice President of Finance & Accounting	no data	geen gegevens	geen gegevens
Christopher Thurston	Chief Technology Officer	less than a year	geen gegevens	geen gegevens
Andrew Benson	Head of Investor Relations	no data	geen gegevens	geen gegevens
Mayuranki Almaula	Senior Vice President of Overseas Operations & Strategic Alliances	no data	geen gegevens	geen gegevens
Cameron Gundry	Head of Commercialization LATAM/EUR	no data	geen gegevens	geen gegevens
Ivory Chang	Chief Regulatory Affairs Officer	1.3yrs	geen gegevens	geen gegevens
Seth Egan	Chief Commercialization Officer	less than a year	geen gegevens	geen gegevens

0.7yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van C97 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dwight Egan	Chairman & CEO	11.6yrs	US$1.26m	1.15% € 408.8k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	2.7yrs	US$237.50k	geen gegevens
Richard Serbin	Independent Director	7.5yrs	US$298.00k	0.37% € 130.8k
Carl Wittwer	Chairman of Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens
James Nelson	Independent Director	5.3yrs	US$298.00k	0.36% € 128.0k
Noriko Kusukawa	Member of Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens
Edward Murphy	Independent Director	5.4yrs	US$298.00k	0.40% € 141.9k
Eugene Durenard	Independent Director	5.4yrs	US$298.00k	0.36% € 128.0k
Karen Carroll	Member of Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens
Anne Wyllie	Member of Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van C97 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Co-Diagnostics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

High number of new and inexperienced directors

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Recent updates

Co-Diagnostics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.31 loss in 2Q 2023)

Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

First quarter 2024 earnings released: US$0.31 loss per share (vs US$0.20 loss in 1Q 2023)

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released: US$1.20 loss per share (vs US$0.45 loss in FY 2022)

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.043 loss in 3Q 2022)

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.083 loss in 2Q 2022)

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Share price stability

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.34 profit in 1Q 2022)

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.45 loss per share (vs US$1.27 profit in FY 2021)

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.34 profit in 2Q 2021)

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.28 in 1Q 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. (NasdaqCM:CODX) completed the acquisition of Advanced Conceptions, Inc.

Co-Diagnostics, Inc. (NasdaqCM:CODX) entered into an Agreement and Plan of Merger to acquire Idaho Molecular Inc.

Third quarter 2021 earnings released: EPS US$0.40 (vs US$0.56 in 3Q 2020)

Co-Diagnostics, Inc. to Introduce at Home/Point of Care Device at AACC on Sept 28

Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$0.34 (vs US$0.54 in 2Q 2020)

Co-Diagnostics, Inc. Provides Earnings Guidance for the Third Quarter 2021

Investor sentiment improved over the past week

Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from Russell 3000E Index

Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.28 (vs US$0.047 loss in 1Q 2020)

Co-Diagnostics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS US$1.59 (vs US$0.37 loss in FY 2019)

Co-Diagnostics Provides Earnings Guidance for the First Quarter of 2021

Co-Diagnostics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Co-Diagnostics, Inc. Announces the Development of A New Point-Of-Care/At Home PCR Diagnostic Testing, Screening and Surveillance Platform

Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based Covid-19 PCR Test Through Walgreens Find Care®

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. Announces CFO Chnages

New 90-day high: €16.20

Investor sentiment improved over the past week